FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
 
 
TXT New Policy Brings Corporate Behavior Changes: Yates
05/17/2016
 
 
TXT FDA Concerned with Repeat Inspectional Findings
05/16/2016
 
 
TXT FDA Delays Generic Drug Labeling Final Rule Until 2017
05/19/2016
 
 
TXT Senate Appropriators Approve $49 Million Boost in FDA 2017 Budget
05/18/2016
 
 
TXT Reps Say FDA Slow to Implement Lab Safety
05/19/2016
 
 
TXT B. Braun Pays $8 Million to Settle Contaminated Syringes Case
05/20/2016
 
 
TXT Groups Want ‘Deemed License’ Policy Changes
05/18/2016
 
 
TXT Recalled Medical Device/Drug Unit Numbers Down: Stericycle
05/19/2016
 
 
TXT CMS Reverses Opposition to UDIs in Claims Forms
05/17/2016
 
 
TXT Draft Guide on Using e-Health Records in Trials
05/16/2016
 
 
TXT Product Approval Summaries
05/22/2016
 
 
TXT Since Our Last Issue ...
05/22/2016
 
 
TXT Latest Federal Register Notices
05/22/2016
 
 
TXT FDA Awards $20 Million Contract on Generic Drug Research
05/20/2016
 
 
TXT Petition Seeks All Unapproved Fluoride Products Off Market
05/20/2016
 
 
TXT Panel to Review Twice Rejected Remoxy for Pain
05/20/2016
 
 
TXT FDA Drug Safety Alert on Ketoconazole Tablets
05/19/2016
 
 
TXT FDA Asked for Dental Amalgam Patient Labeling
05/19/2016
 
 
TXT Put RLD Petition Designations in GDUFA 2: Lawyer
05/19/2016
 
 
TXT NIH Awards $15 Million in Grants to Study Genomics
05/18/2016
 
 
TXT Latest FDA Warning Letters
05/17/2016
 
 
TXT Another Failure-to-Update Case Preempted
05/17/2016
 
 
TXT Lincare Warned About Sterile Drug Violations
05/17/2016
 
 
TXT New Recommendations for Data Monitoring Committees
05/16/2016
 
 
 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving